Pharmacogenetics of irinotecan disposition and toxicity: A review

Current Clinical Pharmacology

Volumn 5, Issue 3, 2010, Pages 209-217

  Fujita, Ken ichi ^a   Sparreboom, Alex ^b  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Irinotecan; Pharmacogenetics; Pharmacokinetics; Toxicity; UGT1A1; Variability

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ABC TRANSPORTER; CAPECITABINE; CARBOXYLESTERASE; CISPLATIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A9; IRINOTECAN; MESSENGER RNA; MIDAZOLAM; ORGANIC ANION TRANSPORTER 2; PROTEIN ABCC2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER CELL CULTURE; COLORECTAL CANCER; DIARRHEA; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG GLUCURONIDATION; EPIGENETICS; ETHNIC DIFFERENCE; FEBRILE NEUTROPENIA; GENE ACTIVITY; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC LINKAGE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GILBERT DISEASE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NEUTROPENIA; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMMENDED DRUG DOSE; SIDE EFFECT;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; GLUCURONOSYLTRANSFERASE; HUMANS; NEUTROPENIA; POLYMORPHISM, GENETIC;

EID: 78649307699     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488410791498806     Document Type: Article

References (100)

1. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-37.
2. Negoro S, Fukuoka M, Masuda N, et al. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 1164-8.
3. Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16: 1068-74
4. Rougier P, Van Cutsem E, Bajetta E, et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
5. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7: 2182-94.
6. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
7. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39.
8. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497-500.
9. Freyer G, Ligneau B, Tranchand B, et al. Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice. Cancer Treat Rev 1997; 23: 153-69.
10. Masson E, Zamboni WC. Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes. Clin Pharmacokinet 1997; 32: 324-43.
11. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002; 94: 1883-8.
12. de Jong FA, Mathijssen RH, Xie R, Verweij J, Sparreboom A, Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability, Clin Cancer Res 2004;10:4068-4071.
13. Mathijssen RH, Verweij J, de Jonge MJ, et al. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J Clin Oncol 2002; 20: 81-7.
14. Wilkinson GR., Drug metabolism and variability among patients in drug response, N Engl J Med 2005;352:2211-2221.
15. Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54: 3723-5.
16. Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15: 1502-10.
17. Kudoh S, Fukuoka M, Masuda N, et al. Relationship between the pharmacokinetics of irinotecan and diarrhea during combination chemotherapy with cisplatin. Jpn J Cancer Res 1995; 86: 406-13.
18. Bosma PJ, Chowdhury JR, Bakker C, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-5.
19. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 1996; 347: 578-81.
20. Iyer L, Hall D, Das S, et al. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 1999; 65: 576-82.
21. Iyer L, King CD, Whitington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847-54.
22. Ando Y, Saka H, Asai G, et al. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9: 845-7.
23. Wasserman E, Myara A, Lokiec F, et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997; 8: 1049-51.
24. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res 2000; 60: 6921-6.
25. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-8.
26. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-7.
27. Marcuello E, Altes A, Menoyo A, et al. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br J Cancer 2004; 91: 678-82.
28. Rouits E, Boisdron-Celle M, Dumont A, et al. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin Cancer Res 2004; 10: 5151-9.
29. Kweekel DM, Gelderblom H, Van der Straaten T, et al. UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study. Br J Cancer 2008; 99: 275-82.
30. Toffoli G, Cecchin E, Gasparini G, et al. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/ leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 866-71.
31. Massacesi C, Terrazzino S, Marcucci F, et al. Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan based chemotherapy. Cancer 2006; 106: 1007-16.
32. Ruzzo A, Graziano F, Loupakis F, et al. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J 2008; 8: 278-88.
33. Cote JF, Kirzin S, Kramar A, et al. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 2007; 13: 3269-75.
34. Liu CY, Chen PM, Chiou TJ, et al. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma. Cancer 2008; 112: 1932-40.
35. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006; 24: 3061-8
36. Ando Y, Chida M, Nakayama K, Saka H, Kamataki T. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 1998; 8: 357-60.
37. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 1998; 95: 8170-4.
38. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyl-transferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem Mol Biol Int 1998; 46: 21-6.
39. Akaba K, Kimura T, Sasaki A, et al. Neonatal hyperbilirubinemia and a common mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese. J Hum Genet 1999; 44: 22-5.
40. Ando Y, Ueoka H, Sugiyama T, et al. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002; 24: 111-6.
41. Gagne JF, Montminy V, Belanger P, et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 2002; 62: 608-17.
42. Premawardhena A, Fisher CA, Liu YT, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis 2003; 31: 98-101.
43. Sai K, Saeki M, Saito Y, et al. UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin Pharmacol Ther 2004; 75: 501-15.
44. Han JY, Lim HS, Shin ES, et al, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin, J Clin Oncol 2006;24:2237-2244.
45. Jada SR, Lim R, Wong CI, et al. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci 2007; 98: 1461-7.
46. Maruo Y, Nishizawa K, Sato H, Doida Y, Shimada M. Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyl-transferase polymorphism. Pediatrics 1999; 103: 1224-7.
47. Araki K, Fujita K, Ando Y, et al. Pharmacogenetic impact of polymorphisms in the coding region of the UGT1A1 gene on SN-38 glucuronidation in Japanese patients with cancer. Cancer Sci 2006; 97: 1255-9.
48. Minami H, Sai K, Saeki M, et al. Irinotecan pharmacokinetics/ pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet Genomics 2007; 17: 497-504.
49. Akiyama Y, Fujita K, Nagashima F, et al. Genetic testing for UGT1A1*28 and *6 in Japanese patients who receive irinotecan chemotherapy. Ann Oncol 2008; 19: 2089-90.
50. Stewart CF, Panetta JC, O'Shaughnessy MA, et al. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J Clin Oncol 2007; 25: 2594-600.
51. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007; 99: 1290-5.
52. Ichikawa W, Araki K, Fujita K, et al, Re: UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters, J Natl Cancer Inst 2008;100:224-225;author reply 5.
53. Ciotti M, Basu N, Brangi M, Owens IS. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus. Biochem Biophys Res Commun 1999; 260: 199-202.
54. Villeneuve L, Girard H, Fortier LC, Gagne JF, Guillemette C. Novel functional polymorphisms in the UGT1A7 and UGT1A9 glucuronidating enzymes in Caucasian and African-American subjects and their impact on the metabolism of 7-ethyl-10-hydroxy-camptothecin and flavopiridol anticancer drugs. J Pharmacol Exp Ther 2003; 307: 117-28.
55. Ockenga J, Vogel A, Teich N, et al. UDP glucuronosyltransferase (UGT1A7) gene polymorphisms increase the risk of chronic pancreatitis and pancreatic cancer. Gastroenterology 2003; 124: 1802-8.
56. Ritter JK, Chen F, Sheen YY, et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyl-transferase isozymes with identical carboxyl termini. J Biol Chem 1992; 267: 3257-61.
57. Strassburg CP, Nguyen N, Manns MP, Tukey RH. Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 1998; 54: 647-54.
58. Strassburg CP, Strassburg A, Nguyen N, et al. Regulation and function of family 1 and family 2 UDP-glucuronosyltransferase genes (UGT1A, UGT2B) in human oesophagus. Biochem J 1999; 338 (Pt 2): 489-98.
59. Zheng Z, Park JY, Guillemette C, Schantz SP, Lazarus P. Tobacco carcinogen-detoxifying enzyme UGT1A7 and its association with orolaryngeal cancer risk. J Natl Cancer Inst 2001; 93: 1411-8.
60. Strassburg CP, Manns MP, Tukey RH. Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8. J Biol Chem 1998; 273: 8719-26.
61. Radominska-Pandya A LX, Bratton S. Human UDP-glucuronosyl-transferases, UGT1A7, UGT1A8 and UGT1A10, are expressed in hepatic tissue. Drug Metab Rev 2006; 38: 114-5.
62. Fujita K, Ando Y, Nagashima F, et al. Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A1*6 is associated with reduced activity for SN-38 in Japanese patients with cancer. Cancer Chemother Pharmacol 2007; 60: 515-22.
63. Girard H, Villeneuve L, Court MH, et al. The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver. Drug Metab Dispos 2006; 34: 1220-8.
64. Sandanaraj E, Jada SR, Shu X, et al. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. Pharmacogenomics J 2008; 8: 174-85.
65. Saito Y, Sai K, Maekawa K, et a, Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese, Drug Metab Dispos 2009;37:272-276.
66. Cecchin E, Innocenti F, D'Andrea M, et al. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J Clin Oncol 2009; 27: 2457-65.
67. Jass JR, Whitehall VL, Young J, Leggett BA. Emerging concepts in colorectal neoplasia. Gastroenterology 2002; 123: 862-76.
68. Jubb AM, Quirke P, Oates AJ. DNA methylation, a biomarker for colorectal cancer: implications for screening and pathological utility. Ann N Y Acad Sci 2003; 983: 251-67.
69. Lofton-Day C, Lesche R. DNA Methylation markers in patients with gastrointestinal cancers. Current understanding, potential applications for disease management and development of diagnostic tools. Dig Dis 2003; 21: 299-308.
70. Toyota M, Itoh F, Imai K. DNA methylation and gastrointestinal malignancies: functional consequences and clinical implications. J Gastroenterol 2000; 35: 727-34.
71. Jaenisch R, Bird A, Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet 2003;(Suppl 33):245-254.
72. Gagnon JF, Bernard O, Villeneuve L, Tetu B, Guillemette C. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer. Clin Cancer Res 2006; 12: 1850-8.
73. Hosokawa M, Endo T, Fujisawa M, et al. Interindividual variation in carboxylesterase levels in human liver microsomes. Drug Metab Dispos 1995; 23: 1022-7.
74. Khanna R, Morton CL, Danks MK, Potter PM. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res 2000; 60: 4725-8.
75. Atsumi R, Okazaki O, Hakusui H. Metabolism of irinotecan to SN-38 in a tissue-isolated tumor model. Biol Pharm Bull 1995; 18: 1024-6.
76. Guichard S, Terret C, Hennebelle I, et al. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Br J Cancer 1999; 80: 364-70.
77. Ogasawara H, Nishio K, Kanzawa F, et al. Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11. Jpn J Cancer Res 1995; 86: 124-9.
78. van Ark-Otte J, Kedde MA, van der Vijgh WJ, et al. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. Br J Cancer 1998; 77: 2171-6.
79. Jansen WJ, Zwart B, Hulscher ST, et al. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997; 70: 335-40.
80. Kawato Y, Furuta T, Aonuma M, et al. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother Pharmacol 1991; 28: 192-8.
81. Meck MM, Wierdl M, Wagner LM, et al. A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxyl-esterase and CPT-11. Cancer Res 2001; 61: 5083-9.
82. Stubdal H, Perin N, Lemmon M, et al. A prodrug strategy using ONYX-015-based replicating adenoviruses to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. Cancer Res 2003; 63: 6900-8.
83. Wierdl M, Morton CL, Weeks JK, et al. Sensitization of human tumor cells to CPT-11 via adenoviral-mediated delivery of a rabbit liver carboxylesterase. Cancer Res 2001; 61: 5078-82.
84. Cecchin E, Corona G, Masier S, et al. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin Cancer Res 2005; 11: 6901-7.
85. Kim SR, Sai K, Tanaka-Kagawa T, et al. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab Dispos 2007; 35: 1865-72.
86. Kubo T, Kim SR, Sai K, et al. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab Dispos 2005; 33: 1482-7.
87. Schiel MA, Green SL, Davis WI, et al. Expression and characterization of a human carboxylesterase 2 splice variant. J Pharmacol Exp Ther 2007; 323: 94-101.
88. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmaco-genomics 2004; 5: 243-72.
89. Mathijssen RH, Marsh S, Karlsson MO, et al. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res 2003; 9: 3246-53.
90. Sai K, Saito Y, Fukushima-Uesaka H, et al. Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients. Cancer Chemother Pharmacol 2008; 62: 529-37.
91. Mathijssen RH, de Jong FA, van Schaik RH, et al. Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. J Natl Cancer Inst 2004; 96: 1585-92.
92. Rouits E, Charasson V, Petain A, et al. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br J Cancer 2008; 99: 1239-45.
93. de Jong FA, Scott-Horton TJ, Kroetz DL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther 2007; 81: 42-9.
94. Han JY, Lim HS, Yoo YK, et al. Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer 2007; 110: 138-47.
95. Fujita K, Nagashima F, Yamamoto W, et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull 2008; 31: 2137-42.
96. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 2005; 33: 434-9.
97. Han JY, Lim HS, Shin ES, et al, Influence of the organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphisms on irinotecan-pharmacokinetics and clinical outcome of patients with advanced non-small cell lung cancer, Lung Cancer 2008;59:69-75.
98. Yu J, Shannon WD, Watson MA, McLeod HL. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005; 11: 2053-62.
99. Innocenti F, Kroetz DL, Schuetz E, et al. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J Clin Oncol 2009; 27: 2604-14.
100. Han JY, Lim HS, Park YH, Lee SY, Lee JS. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer 2009; 63: 115-20.